Skip to main content

Table 4 Differences in relative improvement* effects toward the healthy population's mean value between the oral B12 treatment and placebo group (RΔ%) at 1 and 4 months

From: Oral vitamin B12 for patients suspected of subtle cobalamin deficiency: a multicentre pragmatic randomised controlled trial

  Relative improvement effect towards healthy population's mean value
Biological marker 1 month RΔ% (CI95%; p-value) 4 months RΔ% (CI95%; p-value)
MMA (μmol/l) Reduction 48.7% (CI95% 29.0:68.3; p < 0.001) 0.2% (CI95% -17.8:18.3; p = 0.979)
Serum cobalamin (pM/l) Increase 26.9% (CI95% 13.9:39.8; p < 0.001) 14.1% (CI95% -3.1:31.3; p = 0.105)
Hcys (μmol/l) Reduction 1.8% (CI95% -16.4:20.0; p = 0.844) 6.7% (CI95% -11.3:24.7; p = 0.455)
  1. * Improvement from baseline compared to what would have been expected had the values become normal (MMA = 0.17 μmol/l, vitamin B12 = 375 pM/l, and Hcys = 10.2 μmol/l).